APA (7th ed.) Citation

AD, M., AR, W., A, K., EB, C., A, W., N, O., . . . J, G. (2024). Direct-acting antiviral therapies for hepatitis C infection: Global registration, reimbursement, and restrictions. The lancet. Gastroenterology & hepatology, 9(4), 366. https://doi.org/10.1016/S2468-1253(23)00335-7

Chicago Style (17th ed.) Citation

AD, Marshall, et al. "Direct-acting Antiviral Therapies for Hepatitis C Infection: Global Registration, Reimbursement, and Restrictions." The Lancet. Gastroenterology & Hepatology 9, no. 4 (2024): 366. https://doi.org/10.1016/S2468-1253(23)00335-7.

MLA (9th ed.) Citation

AD, Marshall, et al. "Direct-acting Antiviral Therapies for Hepatitis C Infection: Global Registration, Reimbursement, and Restrictions." The Lancet. Gastroenterology & Hepatology, vol. 9, no. 4, 2024, p. 366, https://doi.org/10.1016/S2468-1253(23)00335-7.